TriSalus Life Sciences Q2 2025 Earnings Report

TriSalus Life Sciences EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.22
• Beat/Miss: N/A
• One Year Ago EPS: N/A

TriSalus Life Sciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $10.69 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

TriSalus Life Sciences Announcement Details

• Quarter: Q2 2025
• Date: 8/13/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, August 14, 2025
• Conference Call Time: 9:00AM ET

TriSalus Life Sciences (NASDAQ:TLSI) is a clinical-stage medical technology company focused on the development and commercialization of thermoconductive agent systems designed to enhance the precision and efficacy of localized tumor ablation and targeted drug delivery. The company’s proprietary formulations are activated by external energy sources—such as radiofrequency, microwave or laser—to generate focused thermal effects within cancerous and precancerous lesions. By combining heat-sensitive liposomal compounds with image-guided energy devices, TriSalus aims to improve outcomes in the treatment of solid tumors while minimizing damage to surrounding healthy tissue.

Since its founding in 2019, TriSalus has advanced multiple product candidates through preclinical studies and early clinical trials. The company acquired the exclusive rights to a heat-activated liposomal chemotherapy agent and holds an investigational device exemption for its thermal ablation platform. TriSalus’s lead programs include a Phase III trial for a thermally activated doxorubicin formulation and continued development of an adjunctive agent designed to augment ablation zones during interventional oncology procedures. These efforts build on research collaborations with academic medical centers and strategic alliances aimed at accelerating regulatory approvals.

Headquartered in Houston, Texas, TriSalus serves a network of cancer centers and interventional radiology practices across the United States. The company’s products are being evaluated in diverse indications, including primary liver cancer, metastatic disease and soft tissue sarcomas. With plans to expand into international markets, TriSalus is forging partnerships with distributors and clinical cooperatives to support multi-center trials and eventual commercial launch.

Leadership at TriSalus comprises seasoned professionals from biotechnology, medical device and pharmaceutical sectors. Chief Executive Officer Dr. Stefan Hock brings more than two decades of experience in translational oncology research and corporate development. The executive team includes experts in clinical operations, regulatory affairs and manufacturing scale-up, all working to advance the company’s mission of delivering next-generation tools for minimally invasive cancer treatment.